UK-based healthcare consultancy CF has partnered with Canadian health outcomes research firm Medlior Health Outcomes Research to generate policy-grade real-world evidence across two universal health systems, according to a report by Consultancy.uk. The alliance targets pharmaceutical sponsors seeking credible, cross-jurisdictional data to support clinical development, market access, and health economics and outcomes research (HEOR).

Consultancy.uk reported that the collaboration operates under the Access Innovation BioBridge programme, a UK-Canada initiative designed to facilitate cross-border life sciences innovation.

By combining CF's access to linked, pseudonymised NHS England data, covering over 57 million people, with Medlior's population-level provincial administrative datasets covering over five million people in Alberta, the partnership offers a whole-population, cradle-to-grave data resource.

The initial focus is on cardiovascular renal metabolic conditions, including chronic kidney disease (CKD), type 2 diabetes, and obesity, with the aim of generating transportable insights for clinical development and market access.

Jaspreet Grewal, managing partner of the Access Innovation BioBridge Programme, said the collaboration exemplifies exactly what the BioBridge programme was designed to achieve, bringing together world-class capabilities from both countries to create new pathways for life sciences innovation.

Ben Richardson, managing partner of life sciences at CF, said the partnership addresses a critical question for sponsors: "To what extent does evidence generated in one health system transport to another?"

Medlior president Tara Cowling added that Alberta's comprehensive pharmacy data, combined with CF's UK platform, will deliver faster and deeper insights across borders to support decision-grade evidence needs.

The arrangement positions both firms as a credible alternative to US-centric evidence models, which are often affected by coverage gaps and limited historical depth.

Access the full details of this cross-border life sciences partnership here.